AGIOS PHARMACEUTICALS, INC.
About AGIOS PHARMACEUTICALS, INC.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel medicines targeting cellular metabolism for hematologic malignancies, solid tumors, and rare genetic diseases. The company has advanced multiple programs from discovery through clinical development and commercialization, with approved products in pyruvate kinase deficiency and acute myeloid leukemia. It maintains a research platform centered on metabolic enzymes and pathways.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Publicly traded biopharmaceutical company on NASDAQ (AGIO).
- Focuses on cellular metabolism for cancer and rare diseases.
- Rule 144 transaction indicates secondary share sale rather than primary capital raise.
Ask StreetZero about AGIOS PHARMACEUTICALS, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account